Cargando…
FRI056 Effect Of 48 Hour Of Metreleptin In Humans With Lipodystrophy During Controlled Feeding
Disclosure: K.M. Bukhari: None. B. Abel: None. R.J. Brown: None. Introduction: The lipodystrophy (LD) syndromes are a rare group of disorders characterized by a generalized or partial loss of adipose tissue resulting in a deficiency of the adipocyte-secreted hormone leptin. Leptin replacement therap...
Autores principales: | Bukhari, Khulood M, Abel, Brent, Brown, Rebecca J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555120/ http://dx.doi.org/10.1210/jendso/bvad114.067 |
Ejemplares similares
-
SUN-607 Iron Parameters in Patients with Partial Lipodystrophy and Impact of Metreleptin Therapy
por: Boutros, Sabine, et al.
Publicado: (2020) -
SAT676 Severe Recurrent Pancreatitis In A Familial Partial Lipodystrophy Patient On Metreleptin
por: Sargin, Pinar, et al.
Publicado: (2023) -
OR33-02 The Treatment of Partial Lipodystrophy in the Setting of Neutralizing Antibody Against Metreleptin with Leptin Receptor Agonist REGN4461
por: Akinci, Baris, et al.
Publicado: (2020) -
FRI054 Partial Lipodystrophy As A Manifestation Of Autoimmune Polyglandular Syndrome 1
por: Agarwal, Shubham, et al.
Publicado: (2023) -
FRI057 Drug Concentrations And Dosing Considerations For Mibavademab, A Novel Leptin Receptor Agonist, In Individuals With Generalized Lipodystrophy
por: Mendell, Jeanne, et al.
Publicado: (2023)